secwatch.observer — SEC 8-K summary
======================================

Issuer:     AtriCure, Inc. (ATRC)
CIK:        0001323885
Form:       8-K
Filed at:   2024-07-30T23:59:59+00:00
Accession:  0001323885-24-000104
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AtriCure Q2 2024 revenue $116.3M (+15.2% YoY); net loss $0.17/share
-------------------------------------------------------------------

- Worldwide revenue $116.3M, up 15.2% YoY (15.4% constant currency); U.S. $95.5M (+12.5%), international $20.7M (+29.4%).
- Gross margin 74.7%, down 168 bps YoY due to mix and product costs; operating loss $7.2M vs $4.1M loss.
- Net loss per share $0.17 vs $0.11; adjusted EBITDA $7.8M, down $0.2M vs Q2 2023.
- Generated positive cash flow of $8.1M during the quarter.
- CEO cited strong growth from pain management and AtriClip franchises; advancing LeAAPS trial and new product launches.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000104/0001323885-24-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1323885/000132388524000104/atrc-20240730.htm
  HTML page:      https://secwatch.observer/filing/0001323885-24-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer